Run M1 CRC Challenge Assessment (SAMPLE 2)

Your name will be kept confidential to participants and any feedback you provide as an assessor will be forwarded anonymously.

Patient EB is a 42 year old female with a history of metastatic colon adenocarcinoma and a lifetime history of ulcerative colitis, sclerosing cholangitis, and uveitis currently on biologic therapy.  Her treatments to date include a total proctocolectomy, pulmonary metastectomy, followed by systemic therapy with FOLFOX + bevacizumab, and then second-line FOLFIRI.  No previous molecular testing has been performed.  An archival block from her pulmonary metastasis has been referred for molecular testing to help inform the next course of therapy.

DOB: July 2 1980 MRN: 67890

Lab 902 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 903 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 904 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 905 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 906 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 907 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 908 SAMPLE 2

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
Hereditary cancer follow-up
Yes
No
Sensitivity to immune checkpoint inhibitors
Yes
No
KRAS, NRAS, BRAF wildtype
Yes
No
Differentiate negative results from a non-diagnostic results
Yes
No
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No

Lab 901 SAMPLE 2

Please note that results were not submitted in time for assessment. Complete the questions below to the best of your abilities.

REFERENCE RESULTS: MSI-High (MMR-deficient), RAS/RAF wild-type
Yes
No
N/A
Hereditary cancer follow-up
Yes
No
N/A
Sensitivity to immune checkpoint inhibitors
Yes
No
N/A
KRAS, NRAS, BRAF wildtype
Yes
No
N/A
Differentiate negative results from a non-diagnostic results
Yes
No
N/A
Sensitivity to anti-EGFR monoclonal antibody therapy
Yes
No
N/A